1. Home
  2. OCUP

OCUP

Ocuphire Pharma Inc.

Logo Ocuphire Pharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Founded: N/A Country:
United States
United States
Employees: N/A City: FARMINGTON HILLS
Market Cap: 44.4M IPO Year: N/A
Target Price: $19.00 AVG Volume (30 days): 226.6K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.46 EPS Growth: N/A
52 Week Low/High: $1.71 - $6.60 Next Earning Date: 05-13-2024
Revenue: $19,049,000 Revenue Growth: -52.20%
Revenue Growth (this year): 39.44% Revenue Growth (next year): 153.74%

Share on Social Networks: